胃癌免疫治疗困境与未来方向

doi:10.11904/j.issn.1002-3070.2021.06.013

实用肿瘤学杂志 ›› 2021, Vol. 35 ›› Issue (6): 552-556.doi: 10.11904/j.issn.1002-3070.2021.06.013

胃癌免疫治疗困境与未来方向

于园园, 孟千皓综述, 王广雨审校

哈尔滨医科大学附属肿瘤医院(哈尔滨 150081)

收稿日期:2020-11-21 修回日期:2021-02-04 出版日期:2021-12-28 发布日期:2021-12-17
通讯作者: 王广雨,E-mail:wangguangyu03@163.com
作者简介:于园园,女,(1996-),硕士研究生,从事消化道肿瘤化疗、靶向及免疫治疗的研究。
基金资助:
海燕基金重点项目(编号:JJZD2018-05);黑龙江省中医药管理局中医药科研项目(编号:ZHY16-109);黑龙江省博士后启动基金(编号:JJZD2018-05)

Dilemma and future direction of gastric cancer immunotherapy

YU Yuanyuan, MENG Qianhao, WANG Guangyu

Harbin Medical University Cancer Hospital,Harbin 150081,China

Received:2020-11-21 Revised:2021-02-04 Online:2021-12-28 Published:2021-12-17

摘要/Abstract

摘要： 中国是胃癌高发国家,新发病例数约占全球的44%,而且胃癌中晚期患者比例大,生存率低,经济负担重。尽管晚期胃癌的化疗方案也在不断改进,但疗效仍然有限。靶向药物除曲妥珠单抗在HER2阳性的晚期胃癌患者中获得了疗效改善,其他的靶向药物在晚期胃癌患者中疗效欠佳。近年来,在胃癌领域掀起了免疫治疗研究热潮,也为胃癌的治疗带来曙光。本文回顾了晚期胃癌免疫治疗的研究进展,并阐述了目前胃癌免疫治疗所面临的困境以及未来探索方向。

关键词: 胃癌, 免疫检查点抑制剂, 分子标志物

Abstract: China is a country with a high incidence of gastric cancer.The number of new cases accounts for about 44% of the world.Moreover,the proportion of patients with advanced gastric cancer is large,the survival rate is low,and the economic burden is serious.Although chemotherapy regimens for advanced gastric cancer are constantly improving,the efficacy is still limited.Targeted drugs except trastuzumab have improved efficacy in HER2-positive advanced gastric cancer patients,and other targeted drugs have poor efficacy in advanced gastric cancer patients.In recent years,immunotherapy has set off a research boom in the field of gastric cancer,and it has also brought dawn to the treatment of gastric cancer.This article reviews the research progress of immunotherapy for advanced gastric cancer,and elaborates the current dilemmas and future exploration directions for immunotherapy for gastric cancer.

Key words: Gastric cancer, Immune checkpoint inhibitors, Molecular markers

中图分类号:

R735.2

于园园, 孟千皓, 王广雨. 胃癌免疫治疗困境与未来方向[J]. 实用肿瘤学杂志, 2021, 35(6): 552-556.

YU Yuanyuan, MENG Qianhao, WANG Guangyu. Dilemma and future direction of gastric cancer immunotherapy[J]. Journal of Practical Oncology, 2021, 35(6): 552-556.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.06.013

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I6/552

参考文献

1 周家琛,郑荣寿,庄贵华,等.2000-2015年中国肿瘤登记地区胃癌发病趋势及年龄变化[J].实用肿瘤学杂志,2020,34(1):1-5.
2 Muro K,Van Cutsem E,Narita Y,et al.Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer:a JSMO-ESMO initiative endorsed by CSCO,KSMO,MOS,SSO and TOS[J].Ann Oncol,2019,30(1):19-33.
3 Japanese Gastric Cancer Association.Japanese gastric cancer treatment guidelines 2018(5th edition)[J].Gastric Cancer,2021,24(1):1-21.
4 Fuchs CS,Doi T,Jang RW,et al.Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer:phase 2 clinical KEYNOTE-059 trial[J].JAMA Oncol,2018,4(5):e180013.
5 Kang YK,Boku N,Satoh T,et al.Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens(ONO-4538-12,ATTRACTION-2):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2017,390(10111):2461-2471.
6 Alsaab HO,Sau S,Alzhrani R,et al.PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy:mechanism,combinations,and clinical outcome[J].Front Pharmacol,2017,8:561.
7 Zhou KI,Peterson B,Serritella A,et al.Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy[J].Clin Cancer Res,2020,26(24):6453-6463.
8 Shitara K,Van Cutsem E,Bang YJ,et al.Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line,advanced gastric cancer:the KEYNOTE-062 phase 3 randomized clinical trial[J].JAMA Oncol,2020,6(10):1571-1580.
9 Moehler M,Shitara K,Garrido M,et al.LBA6_PR Nivolumab(nivo)plus chemotherapy(chemo)versus chemo as first-line(1L)treatment for advanced gastric cancer/gastroesophageal junction cancer(GC/GEJC)/esophageal adenocarcinoma(EAC):first results of the CheckMate 649 study[J].Ann Oncol,2020,31(4):1191.
10 Boku N,Ryu MH,Kato K,et al.Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated,unresectable,advanced,or recurrent gastric/gastroesophageal junction cancer:interim results of a randomized,phase II trial(ATTRACTION-4)[J].Ann Oncol,2019,30(2):250-258.
11 Rha SY,Lee CK,Kim HS,et al.Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer:a multi-institutional phase Ib/II trial of first-line triplet regimen(pembrolizumab,trastuzumab,chemotherapy)for HER2-positive advanced gastric cancer(AGC)[J].J Clin Oncol,2020,38(18):3081.
12 Homann N,Lorenzen S,Schenk M,et al.Interim safety analysis of the DANTE trial:perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma-a randomized,open-label phase II trial of the German Gastric Group at the AIO and SAKK[J].J Clin Oncol,2020,38(18):4549.
13 Wang X,Wang Y,Tang Z,et al.578P Interim analysis of a phase II study of SHR-1210 combined with neoadjuvant chemoradiation in patients with locally advanced proximal stomach adenocarcinoma(Neo-PLANET)[J].Ann Oncol,2020,31(4):491.
14 Kelly RJ,Ajani JA,Kuzdzal J,et al.LBA9_PR adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer(EC/GEJC)following neoadjuvant chemoradiation therapy(CRT):first results of the CheckMate 577 study[J].Ann Oncol,2020,31(4)1193-1194.
15 Hara H,Shoji H,Takahari D,et al.Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma(NivoRam study)[J].J Clin Oncol,2019,37(4):129.
16 Fukuoka S,Hara H,Takahashi N,et al.Regorafenib plus Nivolumab in patients with advanced gastric or colorectal cancer:an Open-Label,Dose-Escalation,and Dose-Expansion phase Ib trial(REGONIVO,EPOC1603)[J].J Clin Oncol,2020,38(18):2053-2061.
17 Markham A,Keam SJ.Camrelizumab:First globle approval[J].Drugs,2019,79(12):1355-1361.
18 Alsina M,Moehler M,Hierro C,et al.Immunotherapy for gastric cancer:A focus on immune checkpoints[J].Target Oncol,2016,11(4):469-477.
19 Lawrence MS,Stojanov P,Polak P,et al.Mutational heterogeneity in cancer and the search for new cancer-associated genes[J].Nature,2013,499(7457):214-218.
20 Rikova K,Guo A,Zeng Q,et al.Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer[J].Cell,2007,131(6):1190-1203.
21 Mishima S,Kawazoe A,Nakamura Y,et al.Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer[J].J Immunother Cancer,2019,7(1):24.
22 Kim ST,Cristescu R,Bass AJ,et al.Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer[J].Nat Med,2018,24(9):1449-1458.
23 Chen C,Zhang F,Zhou N,et al.Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer:a systematic review and meta-analysis[J].Oncoimmunology,2019,8(5):e1581547.
24 Tabernero J,Cutsem EV,Bang YJ,et al.Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction(G/GEJ)adenocarcinoma:the phase III KEYNOTE-062 study[J].J Clin Oncol,2019,37(18):4007.
25 Wainberg ZA,Fuchs CS,Tabernero J,et al.Efficacy of pembrolizumab(pembro)monotherapy versus chemotherapy for PD-L1-positive(CPS ≥10)advanced G/GEJ cancer in the phase II KEYNOTE-059(cohort 1)and phase III KEYNOTE-061 and KEYNOTE-062 studies[J].J Clin Oncol,2020,38(18):427.
26 Cocco E,Scaltriti M,Drilon A.NTRK fusion-positive cancers and TRK inhibitor therapy[J].Nat Rev Clin Oncol,2018,15(12):731-747.
27 Ohtsu A,Shah MA,Van Cutsem E,et al.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer:a randomized,double-blind,placebo-controlled phase III study[J].J Clin Oncol,2011,29(30):3968-3976.

[1]	邬丽婷, 李大兵, 邓小霞, 李柏松. 2013—2020年重庆市北碚区胃癌疾病负担变化趋势及预测[J]. 实用肿瘤学杂志, 2021, 35(6): 495-499.
[2]	陈奕心, 孙轶华, 程洋洋, 何凯桐, 郭婷. 术前炎症相关指标与可切除胃癌患者预后的相关性[J]. 实用肿瘤学杂志, 2021, 35(6): 517-522.
[3]	刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.
[4]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.
[5]	穆慧娟, 李海娜, 吕艺, 孙丽华, 王丽娟, 礼彦侠, 于飞, 潘国伟, 刘莉. 辽宁省三城市居民胃癌10年生存率及其影响因素分析[J]. 实用肿瘤学杂志, 2021, 35(4): 339-343.
[6]	马明瑞, 连洁, 刘超, 娄长杰, 张艳桥. 消化系统肿瘤“免疫治疗前移”的探索[J]. 实用肿瘤学杂志, 2021, 35(3): 258-262.
[7]	王萌萌, 连洁, 李恒震, 张艳桥. 胃肠胰神经内分泌肿瘤的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 154-159.
[8]	杜昕,曲泽,赵选忠,侯明星,王峰. miRNA-126和K-Ras及MMP-7在胃癌中的表达及其相关性分析[J]. 实用肿瘤学杂志, 2021, 35(1): 23-27.
[9]	石琳娜, 隋红. 原发性肝癌免疫检查点抑制剂治疗的进展与挑战[J]. 实用肿瘤学杂志, 2020, 34(6): 560-564.
[10]	尹松祥. Copine-8在胃癌组织中的表达与临床病理特征及预后的相关性[J]. 实用肿瘤学杂志, 2020, 34(5): 430-435.
[11]	李健, 马麒, 任瑾, 呼圣娟. 胃癌影响因素研究进展[J]. 实用肿瘤学杂志, 2020, 34(5): 466-470.
[12]	石琳娜, 隋红. 早期胃癌淋巴结转移评估方法的研究现状[J]. 实用肿瘤学杂志, 2020, 34(3): 286-290.
[13]	周家琛, 郑荣寿, 庄贵华, 张思维, 曾红梅, 陈茹, 王少明, 孙可欣, 邹小农, 魏文强, 赫捷. 2000—2015年中国肿瘤登记地区胃癌发病趋势及年龄变化[J]. 实用肿瘤学杂志, 2020, 34(1): 1-5.
[14]	戴丹, 贾尚春, 陈叶纪, 贺琴, 查震球, 刘志荣. 安徽省肿瘤登记地区2015年胃癌发病与死亡[J]. 实用肿瘤学杂志, 2020, 34(1): 6-10.
[15]	王鸣, 孙梯业. PFKFB4对胃癌细胞侵袭和迁移能力的影响及其作用[J]. 实用肿瘤学杂志, 2020, 34(1): 37-42.

胃癌免疫治疗困境与未来方向

Dilemma and future direction of gastric cancer immunotherapy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价